News

As Alzheimer's disease progresses, behavioral and psychiatric issues become common, distressing, and even dangerous for ...
The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...
Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope.
Cognition Therapeutics Inc. (NASDAQ:CGTX) saw its stock climb sharply by 75% following a productive end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) concerning its Alzheimer’s ...
Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...
The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...
China's top health authority has banned the use of a minimally invasive surgical procedure to treat Alzheimer's disease. The ...
Remarkable new findings about the sugar stores in neurons have unlocked an entire new method of treating Alzheimer's disease ...
Some breast cancer survivors may have a slightly reduced risk for Alzheimer’s disease, though the benefit appears to be ...
Breast cancer treatment might offer protection against Alzheimer's disease, with a study of 70,000 survivors showing lower ...
Breast cancer survivors treated with radiation therapy have an 8% lower risk of developing Alzheimer’s disease, albeit only ...
Breast cancer radiation therapy might protect against Alzheimer's as new research reveals an unexpected benefit changing how ...